Only in Titles

           Search results for: C-erbB-2 HER-2 neu Antibody   

paperclip

#19827890   // Save this To Up

Lack of elevated HER2/neu expression in epithelial dysplasia and oral squamous cell carcinoma in Iran.

The role of the HER family in oral squamous cell carcinomas (OSCCs) is not well-defined. This study was aimed to assess the frequency of HER2/neu overexpression in oral carcinogenesis.

1112 related Products with: Lack of elevated HER2/neu expression in epithelial dysplasia and oral squamous cell carcinoma in Iran.

Oral cavity squamous cell Esophageal squamous cell Lung squamous cell carcin Cervix squamous cell carc Esophagus squamous cell c Esophagus squamous cell c Skin squamous cell carcin Esophageal squamous cell Oral squamous cell cancer Esophagus squamous cell c Multiple lung carcinoma ( Kidney clear cell carcino

Related Pathways

paperclip

#7991280   // Save this To Up

Analysis of cerbB2 expression using a panel of 6 commercially available antibodies.

Results are presented of a study comparing cerbB2 (neu or Her2) expression as assessed immunohistochemically in breast neoplasia using a panel of 6 commercially available antibodies. The antibodies were examined utilizing conventional formalin fixed paraffin embedded tissue, and compared with molecular analysis of gene amplification. The aim was to determine the practical utility of each antibody, assessing ease of use, specific and non-specific staining characteristics, and expense, thus allowing a specific recommendation as to antibody of choice for immunohistochemical assessment of cerbB2 expression. Reassuringly, amongst the 38 breast lesions (36 carcinomas, 2 fibroadenomas) subjected to immunohistochemically (IHC) with the panel of 6 antibodies (Ab), no gross discrepancy of staining pattern was seen. Of the 38 cases, 10 were positive (26%), where at least one Ab demonstrated clear cytoplasmic membrane staining. Of a total of 45 breast lesions (43 carcinomas, 2 fibroadenomas), including all those examined by IHC, the total number of cases showing cerbB2 amplification by DNA analysis was 14 (31%). Using the DNA amplification as a base line for comparison, one Ab (No. 4) was found to stain 6 of the 14 cases of breast carcinoma that were assessed as showing amplification at the DNA level. Four Abs (1,3,5,6) stained 5 of these cases. However, Abs 3,4 and 6 displayed artefactual cytoplasmic staining (in the absence of membrane staining) that precluded the practical use of these reagents. Therefore, based on additional considerations of cost and ease of use, Ab No. 1 was finally chosen for recommendation from the 6 Ab panel.

1152 related Products with: Analysis of cerbB2 expression using a panel of 6 commercially available antibodies.

Rabbit Anti-Rat Androgen Mouse Anti-CMV 66kDa NA A Rabbit Anti-Human GAD 65k Mouse Anti-CMV 66kDa cyto Mouse Anti-Cytomegaloviru Astra Blue 6GLL, Stain fo Mouse Anti-Cytomegaloviru Mouse Anti-CMV 65kDa LA A 2-Amino-4-chloro-3-nitrop Goat Anti-Human BDH2 DHRS Mouse Anti-Influenza B Ma Mouse Anti-Human MIP-3 al

Related Pathways